Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $18
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $18.
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $24 to $18.